Navigation Links
Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance
Date:1/28/2010

g costs included in operating results are summarized below:

    
    
    
    
    Restructuring costs                        Three Months Ended
                                               ------------------
                                                                    
                                      January 2,    October 3,   December 27,
                                        2010          2009           2008
                                        ----          ----           ----
    Cost of sales                       $309          $743         $3,022
    Research & development               409           519            466
    Selling, general &
     administrative                      518           412            618
                                         ---           ---            ---
    Impact on income (loss)
     from operations                  $1,236        $1,674         $4,106
                                      ------        ------         ------
    
    

For the quarters ended January 2, 2010, October 3, 2009, December 27, 2008, the impact on net income (loss), net of tax was $813 ($0.03 per diluted share), $1,054 ($0.04 per share), and $2,613 ($0.11 per diluted share), respectively.

(C) The quarter ended January 2, 2010 includes a $2,185 ($1,438 net of tax ($0.06 per diluted share)) net receipt from the settlement of litigation resulting from our internal stock option investigation.  The quarter ended October 3, 2009 includes $192 ($121 net of tax ($0.00 per share)) of costs related to litigation resulting from our internal stock option investigation. The quarter ended December 27, 2008 includes $441
'/>"/>

SOURCE Coherent, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Coherent, Inc. to Webcast Third Fiscal Quarter 2008 Results
2. Coherent, Inc. Announces Termination of SEC Informal Inquiry
3. Coherent, Inc. to Webcast Fourth Fiscal Quarter 2007 Results
4. Coherent, Inc. Receives Expected Letter from NASDAQ
5. Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share
6. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
7. Medicago reports positive Phase I results for its avian flu pandemic vaccine
8. Neogen Reports 18% Increase in Net Income
9. EntreMed Reports Receipt of Third Quarter Royalty Payment
10. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
11. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical ... segments, including the molecular diagnostics industry. BCC Research reveals in its new report that ... lower test costs, and a growing need for better diagnostics as part of a ...
(Date:7/1/2015)... Ariz. , July 1, 2015 Isagenix ... it has earned three Gold, three Silver, and three ... Awards gala held in Chicago ... as the premier business awards program in the U.S. ... recognizes our company,s strength in developing leaders, cultivating talent, ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 (IP66) Medical Joysticks ... Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. Original ... will increase healthcare worker safety and reduce financial costs. , CTI Electronics announces ...
(Date:6/30/2015)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today ... have approved the resolutions relating to: (i) a ... units at a price of $2.67 per unit ... of one common share and 0.075358 common share ... million; and (ii) the amendment to Resverlogix,s articles ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... 24 , - ... Life,Science Partners and Novartis Option Fund , ... discovery company focused on drugs,targeting G-protein-coupled receptors (GPCRs), ... of equity finance in a successful Series A,private ...
... Inc.,(NYSE: SNN , LSE: SN) Orthopaedic Reconstruction ... instrumentation for use in total,knee replacement surgery. The VISIONAIRE ... x-rays to create custom surgical instrumentation for,use with the ... , By using instruments designed ...
... EAST LONGMEADOW, Mass., Feb. 23 Texcel Medical, ... development and contract manufacturing company, has announced ... CEO.Smith will oversee all functions at Texcel ... by providing the manufacturing infrastructure and expertise they ...
Cached Biology Technology:Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets 2Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets 3Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets 4Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets 5Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 2Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 3Texcel Medical Appoints Barry Smith as President, CEO 2
(Date:6/25/2015)... , June 25, 2015  Imagine a tool ... toward a healthier, happier life. That,s exactly what USANA,s ... to do. The cutting-edge, portable health program provides a ... solutions to help improve your lifestyle and nutrition. ... dinner and gala Wednesday night, USANA,s THA was honored ...
(Date:6/24/2015)... June 24, 2015 This report provides market ... next six years. It contains an analysis of the ... with their impact from the short, medium, and long ... the industry, market, and technology trends that currently, prevail ... of concerned authorities to efficiently manage the increasing marine ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... a key role in glucose regulation and the development of type ... journal Nature . If the hypothesis is correct, it may ... this disease, which is projected to affect one in three adults ... author Dr. Michael W. Schwartz, director of the Diabetes and Obesity ...
... 2013) A human clinical study of older adults ... natural dietary supplement created by Natura Therapeutics, ... to age-matched individuals taking a placebo. Cognition includes processes ... The company,s study, Nutraceutical Intervention Improves Older ...
... study shows that the reduction of pollution emissions from power ... quality of the water that ends up in the Chesapeake ... Center for Environmental Science confirms that as the amount of ... response to the Clean Air Act, the amount of nitrogen ...
Cached Biology News:Brain may play key role in blood sugar metabolism and development of diabetes 2Natura Therapeutics product shown to improve decision making skills in older adults 2Clean Air Act has led to improved water quality in the Chesapeake Bay watershed 2
iEMS Thermal Microplate Holder...
...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
... oligonucleotides: PTOs are internucleotide modifications, ... backbone is replaced by a sulphur atom. ... degradation. PTOs are available as ... Oligonucleotides with thio-caps ...
Biology Products: